[Amiodarone-induced pleuropneumopathies: experience 1983-1993 in a drug vigilance Regional Center].
The authors present the results of a ten year retrospective analysis about amiodarone-induced pulmonary toxicity. Only cases without any etiology (after complete explorations made in hospital), and judged probably imputable to amiodarone treatment were kept. This work finds all characteristics usually described with amiodarone pulmonary toxicity: dyspnea, cough, weight loss, restrictive lung disease and interstitial infiltration in the chest roentgenogram. It shows three another points: pulmonary disease is more frequent during first and fourth years of amiodarone treatment, pneumopathy occurs more rapidly in patients with a previous history of pulmonary disease, and patients with amiodarone lung toxicity may have elevation in lactate dehydrogenase activity.
Service de Pharmacologie clinique, Centre Hospitalier Universitaire, Faculté de Médecine, Toulouse.
V
V
Graille
M
M
Lapeyre-Mestre
J L
JL
Montastruc
D000368:Aged; D000369:Aged, 80 and over; D000638:Amiodarone / Q000009:adverse effects*; D005260:Female; D005602:France / Q000453:epidemiology; D006801:Humans; D008171:Lung Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D010995:Pleural Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000453:epidemiology
D000638:Amiodarone
Pleuro-pneumopathies à l'amiodarone: expérience 1983-1993 d'un Centre régional de Pharmacovigilance.